28216278|t|Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era
28216278|a|Bone metastases (BMs) occur commonly in patients with metastatic renal cell carcinoma (mRCC). Tyrosine kinase inhibitors (TKIs) have improved the outcomes for patients with mRCC. However, data on the outcomes of mRCC patients with BMs treated with TKIs are limited. We describe the outcomes of patients with BMs treated with TKI therapy and compare them with the outcomes from a pre-TKI group. Using an institutional tumor registry, a retrospective review of patients with mRCC from 2002 to 2003 and 2006 to 2007 was performed. The baseline characteristics were analyzed, and overall survival (OS) was estimated using the Kaplan-Meier method. The predictors of OS were analyzed using Cox regression analysis. The data from 375 patients were reviewed. Of these patients, 188 (50%) started treatment with TKIs and 187 (50%) had started treatment in the pre-TKI era. The distribution of patient characteristics was similar. The sites of organ metastases were equally distributed, including BMs in 48% of the patients in each cohort. The median OS for the patients treated in the TKI era was 22 months (95% confidence interval [CI], 17-25 months) compared with 14 months (95% CI, 10-19 months; P < .01) for the historical controls. A subset analysis of patients with BM in the TKI era demonstrated a median OS of 24 months (95% CI, 17-28 months) compared with 18 months (95% CI, 10-21 months; P < .01) in pre-TKI era. The predictors of shorter OS were a higher Memorial Sloan Kettering Cancer Center score; liver, lung, and brain metastases; and multiple sites of BMs (hazard ratio, 1.38; 95% CI, 1.02-1.91; P = .04). The rate of new BM development was the same in the pre- and post- TKI era. The rate of BM development was the same in the pre- and post- TKI era. The management of BMs in patients with mRCC remains challenging.
28216278	0	8	Outcomes	T081	C0086749
28216278	12	20	Patients	T101	C0030705
28216278	26	57	Metastatic Renal Cell Carcinoma	T191	C0278678
28216278	62	77	Bone Metastases	T191	C0153690
28216278	85	101	Targeted Therapy	T061	C2985566
28216278	102	105	Era	T079	C0681698
28216278	106	121	Bone metastases	T191	C0153690
28216278	123	126	BMs	T191	C0153690
28216278	146	154	patients	T101	C0030705
28216278	160	191	metastatic renal cell carcinoma	T191	C0278678
28216278	193	197	mRCC	T191	C0278678
28216278	200	226	Tyrosine kinase inhibitors	T121	C1268567
28216278	228	232	TKIs	T121	C1268567
28216278	239	247	improved	T033	C0184511
28216278	252	260	outcomes	T081	C0086749
28216278	265	273	patients	T101	C0030705
28216278	279	283	mRCC	T191	C0278678
28216278	294	298	data	T078	C1511726
28216278	306	314	outcomes	T081	C0086749
28216278	318	322	mRCC	T191	C0278678
28216278	323	331	patients	T101	C0030705
28216278	337	340	BMs	T191	C0153690
28216278	341	353	treated with	T061	C0332293
28216278	354	358	TKIs	T121	C1268567
28216278	363	370	limited	T169	C0439801
28216278	388	396	outcomes	T081	C0086749
28216278	400	408	patients	T101	C0030705
28216278	414	417	BMs	T191	C0153690
28216278	418	430	treated with	T061	C0332293
28216278	431	434	TKI	T121	C1268567
28216278	435	442	therapy	T061	C0087111
28216278	447	454	compare	T052	C1707455
28216278	469	477	outcomes	T081	C0086749
28216278	485	498	pre-TKI group	T121	C1268567
28216278	509	537	institutional tumor registry	T170	C1315080
28216278	541	561	retrospective review	T062	C0035363
28216278	565	573	patients	T101	C0030705
28216278	579	583	mRCC	T191	C0278678
28216278	623	632	performed	T169	C0884358
28216278	638	646	baseline	T081	C1442488
28216278	647	662	characteristics	T080	C1521970
28216278	668	676	analyzed	T062	C0936012
28216278	682	698	overall survival	T081	C4086681
28216278	700	702	OS	T081	C4086681
28216278	728	747	Kaplan-Meier method	T170	C0025663
28216278	753	763	predictors	T078	C2698872
28216278	767	769	OS	T081	C4086681
28216278	775	783	analyzed	T062	C0936012
28216278	790	813	Cox regression analysis	T170	C0034980
28216278	819	823	data	T078	C1511726
28216278	833	841	patients	T101	C0030705
28216278	847	855	reviewed	T080	C1709940
28216278	866	874	patients	T101	C0030705
28216278	886	893	started	T080	C1272689
28216278	894	903	treatment	T061	C0087111
28216278	909	913	TKIs	T121	C1268567
28216278	928	939	had started	T080	C1272689
28216278	940	949	treatment	T061	C0087111
28216278	957	964	pre-TKI	T121	C1268567
28216278	965	968	era	T079	C0681698
28216278	974	986	distribution	T169	C1704711
28216278	990	997	patient	T101	C0030705
28216278	998	1013	characteristics	T080	C1521970
28216278	1018	1025	similar	T080	C2348205
28216278	1031	1036	sites	T082	C0205145
28216278	1040	1045	organ	T023	C0178784
28216278	1046	1056	metastases	T191	C0027627
28216278	1070	1081	distributed	T169	C1704711
28216278	1093	1096	BMs	T191	C0153690
28216278	1111	1119	patients	T101	C0030705
28216278	1128	1134	cohort	T098	C0599755
28216278	1140	1146	median	T081	C0876920
28216278	1147	1149	OS	T081	C4086681
28216278	1158	1166	patients	T101	C0030705
28216278	1167	1174	treated	T061	C0332293
28216278	1182	1185	TKI	T121	C1268567
28216278	1186	1189	era	T079	C0681698
28216278	1197	1203	months	T079	C0439231
28216278	1209	1228	confidence interval	T081	C0009667
28216278	1230	1232	CI	T081	C0009667
28216278	1241	1247	months	T079	C0439231
28216278	1249	1257	compared	T052	C1707455
28216278	1266	1272	months	T079	C0439231
28216278	1278	1280	CI	T081	C0009667
28216278	1288	1294	months	T079	C0439231
28216278	1313	1332	historical controls	T098	C2986415
28216278	1343	1351	analysis	T062	C0936012
28216278	1355	1363	patients	T101	C0030705
28216278	1369	1371	BM	T191	C0153690
28216278	1379	1382	TKI	T121	C1268567
28216278	1383	1386	era	T079	C0681698
28216278	1402	1408	median	T081	C0876920
28216278	1409	1411	OS	T081	C4086681
28216278	1418	1424	months	T079	C0439231
28216278	1430	1432	CI	T081	C0009667
28216278	1440	1446	months	T079	C0439231
28216278	1448	1456	compared	T052	C1707455
28216278	1465	1471	months	T079	C0439231
28216278	1477	1479	CI	T081	C0009667
28216278	1487	1493	months	T079	C0439231
28216278	1507	1514	pre-TKI	T121	C1268567
28216278	1515	1518	era	T079	C0681698
28216278	1524	1534	predictors	T078	C2698872
28216278	1538	1545	shorter	T081	C1806781
28216278	1546	1548	OS	T081	C4086681
28216278	1556	1562	higher	T080	C0205250
28216278	1563	1607	Memorial Sloan Kettering Cancer Center score	T081	C0449820
28216278	1609	1614	liver	T191	C0494165
28216278	1616	1620	lung	T191	C0153676
28216278	1626	1642	brain metastases	T191	C0220650
28216278	1648	1662	multiple sites	T082	C0205145
28216278	1666	1669	BMs	T191	C0153690
28216278	1671	1683	hazard ratio	T081	C2985465
28216278	1695	1697	CI	T081	C0009667
28216278	1724	1728	rate	T081	C1521828
28216278	1736	1738	BM	T191	C0153690
28216278	1739	1750	development	T169	C1527148
28216278	1759	1763	same	T080	C0445247
28216278	1786	1789	TKI	T121	C1268567
28216278	1790	1793	era	T079	C0681698
28216278	1799	1803	rate	T081	C1521828
28216278	1807	1809	BM	T191	C0153690
28216278	1810	1821	development	T169	C1527148
28216278	1830	1834	same	T080	C0445247
28216278	1857	1860	TKI	T121	C1268567
28216278	1861	1864	era	T079	C0681698
28216278	1870	1880	management	T058	C0376636
28216278	1884	1887	BMs	T191	C0153690
28216278	1891	1899	patients	T101	C0030705
28216278	1905	1909	mRCC	T191	C0278678
28216278	1918	1929	challenging	T058	C0805586